APA (7th ed.) Citation

Y, S., T, K., K, M., M, K., K, M., Y, T., . . . T, T. (2026). Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Journal for immunotherapy of cancer, 14(4), . https://doi.org/10.1136/jitc-2025-013384

Chicago Style (17th ed.) Citation

Y, Sato, et al. "Carbonic Anhydrase 9 as a Circulating Biomarker and Therapeutic Target in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab." Journal for Immunotherapy of Cancer 14, no. 4 (2026). https://doi.org/10.1136/jitc-2025-013384.

MLA (9th ed.) Citation

Y, Sato, et al. "Carbonic Anhydrase 9 as a Circulating Biomarker and Therapeutic Target in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab." Journal for Immunotherapy of Cancer, vol. 14, no. 4, 2026, https://doi.org/10.1136/jitc-2025-013384.